Haemonetics News

The public may access Mr. Lindop's presentation live via webcast at: http://www.media-server.com/m/p/je7nwq7n Haemonetics is a global healthcare company dedicated to providing innovative blood management solutions for our customers.

A medical device and industrial holding company, both based in Braintree, made the Globe Top 100, an annual ranking of the best performing firms in Massachusetts.

The firm currently has a $47.00 price target on the stock, up from their previous price target of $43.00. A number of other firms have also recently commented on HAE.

Blood management systems provider Haemonetics said it will close its Braintree plant and move manufacturing of disposable products to its facility in Mexico.

Haemonetics recently learned that the U.S. FDA approved Hemerus' New Drug Application for the SOLXA whole blood collection system for eight hour storage of whole blood.

Several other analysts have also recently commented on the stock. Analysts at Zacks downgraded shares of Haemonetics from an "outperform" rating to a "neutral" rating in a research note to investors on Thursday, April 11th.